Dovato Noninferior to Biktarvy at 48 Weeks

Originally published by our sister publication Infectious Disease Special EditionBy Ethan CoveyA two-drug regimen of dolutegravir-lamivudine (DTG/3TC; Dovato, ViiV Healthcare) was noninferior to bictegravir, emtricitabine, and tenofovir alafenamide (BIC/FTC/TAF; Biktarvy, Gilead) for virologic suppression at 48 weeks among adults initiating antiretroviral therapy, according to results from the phase 3b VOGUE trial presented at AIDS 2026, in Rio de Janeiro (oral presentation OAB0106LB and in-pers